Suven Life receives patent for neuro-degenerative molecule

Suven Life Sciences has received approval for product patent from New Zealand for its molecule that will be used in the treatment of neuro-degenerative diseases.

As of now, Suven has a total of 26 patents from New Zealand, including this new patent. The new patent will be valid through 2033.

The Chief Executive Officer of Suven, Venkat Jasti, said that this new patent is for Suven's pipeline of molecules in the CNS arena, which is being improved for cognitive disorders for the medical needs which has not been fulfilled as yet.

These patents will now be complete intellectual properties of Suven and they are obtained through the company's internal research practices.

As per reports, additional chemical entities are going to be improved for the cognitive impairment treatment, which is linked with disorders like Alzheimer’s disease, attention deficient hyperactivity disorder, Huntington’s disease, major depressive disorder, Parkinson's disease and schizophrenia.

The stock of Suven Life Science closed at Rs. 168.15, up by 0.18 per cent on the bourses, on Tuesday's trading session.